Table 2.
Vaccines | Study Time/Reporting Time | Countries or Regions | Enrollments | Observation Duration (Year) | Doses | Efficacy on Conditions | Efficacy, %(95%CI) | Reference |
---|---|---|---|---|---|---|---|---|
Rotarix™ | 2001–2003 | Singapore | 2464 | 1 | 2 | RVGE | 82.0% (N/A) | 231 |
2003–2004 | Latin American, Finland | 63,225 | 1 | 2 | severe RVGE | 84.7% (71.7%-92.4%) | 110 | |
2004–2005 | Europe countries | 3994 | 1 | 2 | RVGE | 78.9% (72.7%-83.8%) | 106 | |
severe RVGE | 90.4% (85.1%-94.1%) | |||||||
2003–2008 | Hong Kong, Singapore, Taiwan | 10,708 | 2 | 2 | severe RVGE | 96.1% (85.1%-99.5%) | 113 | |
3 | 2 | severe RVGE | 96.9% (88.3%-99.6%) | 114 | ||||
2003–2005 | Singapore | 6542 | 3 | 2 | severe RVGE | 95.2% (70.5%-99.9%) | 232 | |
2003–2005 | Hong Kong | 3025 | 3 | 2 | severe RVGE | 96.1% (76.5%-99.9%) | 233 | |
2005 | South Africa, Malawi | 4939 | 1 | 2/3 | severe RVGE | 61.2% (44.0%-73.2%) | 25 | |
2006–2007 | Malawi | 1773 | 3 | 2/3 | severe RVGE | 38.1% (9.8%-57.3%) | 118 | |
RotaTeq™ | 2001–2004 | Belgium, Costa Rica, Finland, Germany, Guatemala, Italy, Jamaica, Mexico, Puerto Rico, Sweden, Taiwan, United States |
70,301 | First RV season | 3 | RVGE | 74% (66.8%-79.9%) | 84 |
severe RVGE | 98% (88.3%-100%) | |||||||
second RV season | RVGE | 62.6% (44.3%-75.4%) | ||||||
severe RVGE | 88% (49.4%-98.7%) | |||||||
2001–2004 | Finland | 23,422 | 3.1 | 3 | RVGE hospitalizations and ED visits | 93.8% (90.8%-95.9%) | 88 | |
2007–2009 | Ghana, Kenya, Mali |
5560 | 2 | 3 | severe RVGE | 39.3% (19.1%-54.7%) | 24 | |
2007–2009 | Bangladesh, Vietnam | 2119 | 2 | 3 | severe RVGE | 48.3% (22.3%-66.1%) | 27 | |
2014–2015 | China | 4173 | At least 14 d after the third dose | 3 | RVGE | 69.3% (54.5%-79.7%) | 95 | |
severe RVGE | 78.9% (59.1%-90.1%) | |||||||
Rotavac™ | 2011–2013 | India | 6799 | 1 | 3 | severe RVGE | 53.6% (35.0%-66.9%) | 133 |
2 | 3 | severe RVGE | 55.1% (39.9%-66.4%) | 132 | ||||
RotaSiil™ | 2014–2015 | Niger | 4137 | 28 d after the third dose | 3 | severe RVGE | 66.7% (49.9%-77.9%) | 144 |
Abbreviations: RV, rotavirus; RVGE, RV gastroenteritis; CI, confidence interval; ED, emergency department; N/A, not applicable.
*These selected clinical trials were chosen in terms of the representative researches and the number of participants more than 1500.